Taiwan
Every company in the roster headquartered in Taiwan.
Every company in the roster headquartered in Taiwan.
11 of 11 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
AP Biosciences Inc.6945 · TPEx | 2 assets: 2 Ph 2 | B1962Phase 2 · Non-Small Cell Lung Cancer | Dec 2026AP203 · Phase 1/2 | — | — | — | — |
Foresee Pharmaceuticals6576 · TPEx | 1 asset: 1 Ph 2 | MirivadelgatPhase 2 · Pulmonary Hypertension Associated with Interstitial Lung Disease | Feb 2028Mirivadelgat · Phase 2 | — | — | — | — |
PharmaEngine4162 · TPEx | 1 asset: 1 Ph 1 | PEP07Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026PEP07 · Phase 1 | — | — | — | — |
Pharmosa Biopharm Inc.6875 · TPEx | 1 asset: 1 Ph 3 | Treprostinil (L606)Phase 3 · Pulmonary Arterial Hypertension | Jul 2029Treprostinil (L606) · Phase 3 | — | — | — | — |
Polaris Group6550 · TWSE | 1 asset: 1 Ph 3 | PegargiminasePhase 3 · Hepatocellular CarcinomaWeak signal | Jan 2027Pegargiminase · Phase 1 | — | — | — | — |
BiopeuticsPrivate | 1 asset: 1 Ph 3 | alprostadilPhase 3 · Heart Failure | Nov 2029alprostadil · Phase 3 | — | — | — | — |
| 1 asset: 1 Ph 2 | LiafensinePhase 2 · Major Depressive DisorderReliable signal | None on record | — | — | — | — | |
GNT Biotech & MedicalsPrivate | 1 asset: 1 Ph 3 | ChidamidePhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal | 31 May 2028Chidamide · Phase 3 | — | — | — | — |
ImmunworkPrivate | 1 asset: 1 Ph 2 | TE-8105Phase 2 · ObesityWeak signal | Feb 2028TE-8105 · Phase 2 | — | — | — | — |
Meridigen BiotechPrivate | 1 asset: 1 Ph 2 | SolizmestrocelPhase 2 · Chronic Obstructive Pulmonary DiseaseWeak signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | TML-6Phase 2 · Alzheimer's DiseaseWeak signal | 30 Apr 2028TML-6 · Phase 2 | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.